

# Sharp HealthCare COVID-19 Treatment Guidelines (V7)

## Intro

The intent of this guideline was to summarize existing clinical framework for clinical management of adult hospitalized patients COVID-19 (Covid) at Sharp HealthCare facilities. Now more than 18 months into the pandemic, and with the availability of excellent and regularly updated guidelines, we refer providers to [NIH COVID Treatment Guidelines](#) as our primary treatment guideline for care at Sharp hospitals and facilities.

For any provider regularly caring for patients with Covid or MIS, please sign up through the [NIH website](#) to receive guideline updates via email.

## Sharp HealthCare Emergency Use Authorization (EUA) Workgroup

To provide safe, effective, and high-value care to our patients with Covid, Sharp HealthCare convened an emergency use authorization (EUA) pharmacy and therapeutics Covid workgroup which reports to HID. This group is composed of physician leaders including all site CMOs, pulmonology, hospitalists, emergency medicine, OB, infectious disease, rheumatology, occupational health, as well as our system pharmacy and ASP experts. The workgroup regularly reviews existing literature on treatments for Covid, with focus on drugs that have received EUA approval, as well as the off-label use of some select agents.

This workgroup may occasionally supplement this document or provide SBAR updates to the medical and pharmacy staff based on the evolving nature of the pandemic, available therapies, drug shortages, and contingency planning needs—such as availability and preference on the use of DMARDs that may not be covered within the scope of NIH Guidelines.

If new and highly promising therapies become available, or existing ones have a serious safety signal, the EUA workgroup may in some instances provide guidelines and workflow support ahead of updated NIH practice recommendations.

We also emphasize NIH's position that "whenever possible, the Panel recommends that promising, unapproved, or unlicensed treatments for COVID-19 be studied in well-designed, controlled clinical trials. This recommendation also applies to drugs that have been approved or licensed for indications other than the treatment of COVID-19. The Panel recognizes the critical importance of clinical research in generating evidence to address unanswered questions regarding the safety and efficacy of potential treatments for COVID-19."

# Sharp HealthCare COVID-19 Treatment Guidelines (V7)

## Diagnostic and Surveillance Testing

[Please refer to NIH guidelines about viral-specific testing for SARS-CoV-2 infection](#)

Sharp HealthCare remains unique among healthcare organizations, reflexively sending nearly 100% of positive PCR cases for viral whole genome sequencing from emergency department and hospitalized patients. De-identified viral genomic profile of our patients are included and regularly updated at [Outbreak.info](#), [SEARCH Alliance](#), and [Nextstrain.org](#).

## Covid Treatment Summary

As of August 2021, we refer providers to the NIH COVID-19 Treatment Guidelines for additional guidance on care for patients with Covid. Information is available for the following and additional topics on the NIH website:

- [Prevention of SARS-CoV-2 Infection](#)
- Non-hospitalized patients [general management](#) and [therapeutic management](#)
- [Hospitalized adults: therapeutic management](#)
- [Critical care](#)
- [Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children \(MIS-C\) \(With Discussion on Multisystem Inflammatory Syndrome in Adults \[MIS-A\]\)](#)
- [Special Considerations in Pregnancy](#)

## Discontinuation of Isolation

Share HealthCare Infection Prevention affirms the updated CDC guidelines for discontinuation of isolation precautions in COVID patients. Please refer to SHIP for reference and further guidance on this important topic. Providers are encouraged to review individual cases with SHIP for case-specific guidance.

Please note that entity-level IP are the ultimate arbiters of whether to continue or discontinue transmission-based precautions in patients with COVID. A summary of their assessment and determinations may be viewed in Cerner under “Interdisciplinary Documentation”, “Infection Prevention Note”.

# Sharp HealthCare COVID-19 Treatment Guidelines (V7)

## Supplemental References

- [IDSA | Guidelines on the Treatment and Management of Patients with COVID-19](#)
- [ACOG | COVID-19 FAQs for Obstetrician-Gynecologists, Obstetrics](#)
- [SMFM | COVID-19 Publications & Clinical Guidance](#)
- [ACOG | COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care](#)
- [CDC | COVID-19 Vaccines While Pregnant or Breastfeeding](#)

## Authors

The authors of this document have no conflicts of interest or disclosures to report.

To reach the authors or to provide feedback on this document, please reach out to:  
Brian Lichtenstein, MD, Hospital Medicine ([brian.lichtenstein@sharp.com](mailto:brian.lichtenstein@sharp.com))

We extend our utmost thanks on the amazing efforts of our writing and editorial team who contributed immensely to prior versions of this project!

- Anticoagulation, Pulmonary Disease: Roland El Ghazal, MD, Pulmonology and Critical Care ([roland.elghazal@sharp.com](mailto:roland.elghazal@sharp.com))
- Antimicrobials: Norihiro Yogo, MD, Infectious Disease ([norhiro.yogo@sharp.com](mailto:norhiro.yogo@sharp.com)), Louis Lteif, PharmD ([louis.lteif@sharp.com](mailto:louis.lteif@sharp.com))
- Endocrinology: Kalman Holdy, MD, Endocrinology ([keholdy@att.net](mailto:keholdy@att.net)), Brandon Bailey, PharmD ([Brandon.Bailey@sharp.com](mailto:Brandon.Bailey@sharp.com))
- Immunomodulators: Louis Lteif, PharmD ([louis.lteif@sharp.com](mailto:louis.lteif@sharp.com))
- Lab Medicine: Omid Bakhtar, MD, Pathology ([omid.bakhtar@sharp.com](mailto:omid.bakhtar@sharp.com))
- Obstetrics/MFM: Joanna Adamczak, MD, Maternal-Fetal Medicine ([Joanna.adamczak@sharp.com](mailto:Joanna.adamczak@sharp.com))